Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-138680

Published: 2020

Journal Articles

A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial

Blood (2018) 132 (Supplement 1): 467.

https://doi.org/10.1182/blood-2018-99-111756

Published: 2018

Journal Articles

Prognostic Impact of ABCA3 Expression in Pediatric Acute Myeloid Leukemia

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Helene Lapillone, Guy Leverger, MD, Etienne Paubelle, MD PhD, Lea Herpe, Catherine Koering, PhD, Christine Ragu, PhD, Yves Bertrand, MD PhD, Eric Wattel, MD PhD

Blood (2016) 128 (22): 1694.

https://doi.org/10.1182/blood.V128.22.1694.1694

Published: 2016

Journal Articles

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Blood (2016) 128 (22): 347.

https://doi.org/10.1182/blood.V128.22.347.347

Published: 2016

Journal Articles

ABCA3 Expression Predicts Response to Gemtuzumab Ozogamicin in AML

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Etienne Paubelle, MD PhD, Xavier Thomas, MD PhD, Lea Herpe, Olivier Nibourel, PharmD, PhD, Claude Preudhomme, MD PhD, Sylvie Castaigne, MD PhD, Hervé Dombret, Eric Wattel, MD PhD

Blood (2016) 128 (22): 3946.

https://doi.org/10.1182/blood.V128.22.3946.3946

Published: 2016

Journal Articles

A Transcriptional- and Posttranscriptional-Based Prognostic Model in Pediatric Acute Myeloid Leukemia

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Helene Lapillone, Guy Leverger, MD, Etienne Paubelle, MD PhD, Lea Herpe, Christine Ragu, PhD, Franck Mortreux, PhD, Yves Bertrand, MD PhD, Eric Wattel, MD PhD

Blood (2016) 128 (22): 2870.

https://doi.org/10.1182/blood.V128.22.2870.2870

Published: 2016

Journal Articles

Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Helene Lapillone, Guy Leverger, MD, Etienne Paubelle, MD PhD, Xavier Thomas, MD PhD, Olivier Nibourel, PharmD, PhD, Claude Preudhomme, MD PhD, Sylvie Castaigne, MD PhD, Hervé Dombret, Lea Herpe, Christine Ragu, PhD, Yves Bertrand, MD PhD, Franck Mortreux, PhD, Eric Wattel, MD PhD

Blood (2016) 128 (22): 3952.

https://doi.org/10.1182/blood.V128.22.3952.3952

Published: 2016

Journal Articles

Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-Dependent Patients with Low-Risk MDS and Iron Overload: The Rythmex Study

Christian Rose, MD, Olivier Fitoussi, MD, Emmanuel Gyan, MD PhD, Maya Hacini, MD, Shanti Amé, MD, Bernadette Corront, MD, Odile Beyne-Rauzy, MD PhD, Didier Innocent Adiko, MD, Elena-Anca Loppinet, MD, Nadia Ali-Ammar, MD, Eric Wattel, MD PhD, Francois Dreyfus, MD, Stéphane Cheze, MD PhD

Blood (2016) 128 (22): 2008.

https://doi.org/10.1182/blood.V128.22.2008.2008

Published: 2016

Journal Articles

Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?

Etienne Paubelle, MD PhD, Sophie Ducastelle, MD, Helene Labussiere, MD, Franck E. Nicolini, MD PhD, Fiorenza Barraco, MD, Adriana Plesa, Gilles A. Salles, Eric Wattel, MD PhD, Xavier Thomas, MD PhD

Blood (2016) 128 (22): 4003.

https://doi.org/10.1182/blood.V128.22.4003.4003

Published: 2016

Journal Articles

A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study

Thomas Prebet, MD, Jacques Delaunay, MD, Eric Wattel, MDPhD, Thorsten Braun, MD PhD, Pascale Cony-Makhoul, MD, Sophie Dimicoli, MD, Stefan Wickenhauser, MD, Julie Lejeune, Sylvie Chevret, Fatiha Chermat, Pierre Fenaux, MD PhD, Norbert Vey

Blood (2015) 126 (23): 2900.

https://doi.org/10.1182/blood.V126.23.2900.2900

Published: 2015

Journal Articles

Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study

Blood (2015) 126 (23): 1665.

https://doi.org/10.1182/blood.V126.23.1665.1665

Published: 2015

Journal Articles

Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Francoise Solly, MD, Catherine Koering, PhD, Aminetou mint Mohamed, PhD, Delphine Maucort-Boulch, MD, Guillaume Robert, PhD, Patrick Auberger, PhD, Pascale Flandrin-Gresta, MDPhD, Lionel Adès, MD PhD, Pierre Fenaux, MD PhD, Olivier Kosmider, MD PhD, Emmanuelle Tavernier-Tardy, MDPhD, Jérôme Cornillon, MD, Denis Guyotat, MDPhD, Lydia Campos, MD PhD, Franck Mortreux, PhD, Eric Wattel, MDPhD

Blood (2015) 126 (23): 2840.

https://doi.org/10.1182/blood.V126.23.2840.2840

Published: 2015

Journal Articles

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Blood (2014) 124 (21): 2324.

https://doi.org/10.1182/blood.V124.21.2324.2324

Published: 2014

Journal Articles

Impact of Initial Body Mass Index (BMI) on Survival Outcome of Patients with Acute Leukemia (AL): Myth or Reality?

Mael Heiblig, MD, Mohamed Elhamri, CRA, Véronique L'Héritier, Hélène Labussière-Wallet, MD, Fiorenza Barraco, MD, Sophie Ducastelle-Leprêtre, MD, Eric Wattel, MD PhD, Mauricette Michallet, MD PhD, Franck E Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3679.

https://doi.org/10.1182/blood.V124.21.3679.3679

Published: 2014

Journal Articles

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Blood (2014) 124 (21): 68.

https://doi.org/10.1182/blood.V124.21.68.68

Published: 2014

Journal Articles

Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, Thomas Prebet, MD PhD, Aspasia Stamatoullas, Christian Recher, MD PhD, Romain Guieze, MD, Emmanuel Raffoux, Krimo Bouabdallah, MD, Mathilde Hunault, Eric Wattel, Laure Stalnikiewicz, MD, Andrea Toma, Herve Dombret, MD, PhD, Norbert Vey, MD PhD, Claude Gardin, MD, Benedicte Samey, Sylvie Chevret, Pierre Fenaux, MD, PhD

Blood (2013) 122 (21): 620.

https://doi.org/10.1182/blood.V122.21.620.620

Published: 2013

Journal Articles

Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM

Blood (2013) 122 (21): 658.

https://doi.org/10.1182/blood.V122.21.658.658

Published: 2013

Journal Articles

Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure

Thomas Prebet, MD, PhD, Thorsten Braun, Odile Beyne-Rauzy, Eric Wattel, MD, PhD, Francois Dreyfus, Aspasia Stamatoulas, MD, Shanti Ame, MD, Jacques Delaunay, MD, Emmanuel Raffoux, Fatiha Chermat, Pierre Fenaux, Norbert Vey

Blood (2012) 120 (21): 3825.

https://doi.org/10.1182/blood.V120.21.3825.3825

Published: 2012

Journal Articles

DEK and WT1 Affect Alternative Splicing of Genes Involved in Hematopoietic Cell Lineage and Resistance to Chemotherapy in Acute Myeloid Leukemia Cells.

Aminetou Mint Mohamed, Morgan Thenoz, Catherine Koering, Pierre Mallinjoud, Didier Auboeuf, Francoise Solly, Meyling Cheok, Olivier Nibourel, Claude Preudhomme, Eric Wattel, Franck Mortreux

Blood (2012) 120 (21): 2392.

https://doi.org/10.1182/blood.V120.21.2392.2392

Published: 2012

Journal Articles

Azacitidine Use in MDS and AML Patients: Best Selection for Better Results

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm. M., Stéphane Morisset, Stat., Carine Champigneulle, CRA, Florence Ranchon, Marie Y. Detrait, MD, Hélène Labussière-Wallet, MD, Sophie Ducastelle, MD, Franck E. Nicolini, MD, PhD, Youcef Chelghoum, MD, Xavier Thomas, MD, Caroline Le jeune, MD, Eric Wattel, MD, PhD, Catherine Rioufol, PharmD, Fiorenza Barraco, MD

Blood (2012) 120 (21): 5070.

https://doi.org/10.1182/blood.V120.21.5070.5070

Published: 2012

NARROW

Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial

A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial

Prognostic Impact of ABCA3 Expression in Pediatric Acute Myeloid Leukemia

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

ABCA3 Expression Predicts Response to Gemtuzumab Ozogamicin in AML

A Transcriptional- and Posttranscriptional-Based Prognostic Model in Pediatric Acute Myeloid Leukemia

Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-Dependent Patients with Low-Risk MDS and Iron Overload: The Rythmex Study

Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?

A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study

Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study

Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Impact of Initial Body Mass Index (BMI) on Survival Outcome of Patients with Acute Leukemia (AL): Myth or Reality?

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM)

Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM

Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure

DEK and WT1 Affect Alternative Splicing of Genes Involved in Hematopoietic Cell Lineage and Resistance to Chemotherapy in Acute Myeloid Leukemia Cells.

Azacitidine Use in MDS and AML Patients: Best Selection for Better Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only